No video visit
All states
GLP-1 weight loss in California
- Visit type
- No video visit required
- Licensing
- Medical Board of California
- Updated
- Licensed by
- Medical Board of California
- Telehealth
- No video visit required
- Semaglutide injections
- Available
- Tirzepatide injections
- Available
- Medicaid
- Limited coverage
- Shipping
- 2–3 business days
California residents — from Los Angeles and San Diego to San Francisco and Sacramento — can now access GLP-1 medications like semaglutide and tirzepatide through telehealth — no commute, no waiting room, no insurance hoops. Pallas Health connects you with a board-certified provider licensed in California who can evaluate your eligibility in under 5 minutes and, if appropriate, write a prescription that ships to any California address in a few business days.
How telehealth prescribing works in California
California permits licensed physicians to establish a patient relationship and prescribe non-controlled medications like GLP-1s through synchronous video or store-and-forward review, provided the standard of care is met.
California requires any provider writing a prescription to a California resident to hold an active California medical license — an out-of-state license is not enough. Every Pallas clinician who treats California patients is independently licensed by the Medical Board of California and practices within its telehealth guidance, which permits establishing the provider-patient relationship over video or through secure asynchronous review when the standard of care can be met. You'll complete a detailed intake, and depending on your history a provider may follow up by message, video, or request additional labs before prescribing. GLP-1s are not controlled substances, so California's stricter controlled-substance telemedicine rules do not apply, but our providers still document a complete history, review contraindications, and arrange follow-up check-ins to monitor response and side effects.
Medicaid & insurance in California
Medi-Cal removed Wegovy®, Zepbound®, and Saxenda® from coverage for weight-loss indications for members 21 and older effective January 1, 2026. FDA-approved GLP-1s remain covered for type 2 diabetes with a diagnosis restriction, with narrow exceptions (Wegovy® for cardiovascular risk reduction or MASH; Zepbound® for obstructive sleep apnea). Compounded products are not covered. Pallas is a cash-pay telehealth service. Medicaid and private insurance do not apply to our prescriptions; pricing is flat and disclosed up front.
Simple cash-pay pricing in California
No insurance, and the same price in every California ZIP code. You see your full price during intake, before you pay anything. One plan price covers your US-licensed provider, check-ins, dose adjustments and care-team messaging, with no membership fee. Medication ships free, and nothing is charged until a clinician prescribes. Cancel anytime. Your clinician helps determine which option is appropriate for you.
Compounded
- Semaglutide injectionsFrom $139
- Tirzepatide injectionsFrom $179
Brand-name
- Wegovy® injectionsFrom $499
- Zepbound® injectionsFrom $499
- Ozempic® injectionsFrom $499
- Mounjaro® injections$1,099/mo
- Wegovy® pillFrom $299
- Foundayo™ pillFrom $299
Semaglutide vs tirzepatide in California
Both are once-weekly injections available to California patients through Pallas, as compounded preparations and as the FDA-approved brand-name products. They work differently: semaglutide activates the GLP-1 receptor, while tirzepatide activates both the GLP-1 and GIP receptors — two of the gut hormones that regulate appetite and fullness.
In SURMOUNT-5, the head-to-head clinical trial of the FDA-approved products, Zepbound® (tirzepatide 10 mg or 15 mg weekly) produced greater average weight loss than Wegovy® (semaglutide 1.7 mg or 2.4 mg weekly) — 20.2% versus 13.7% of body weight over 72 weeks — with broadly similar tolerability. That trial predates Wegovy®'s higher 7.2 mg weekly dose, which reached 18.7% average weight loss over 72 weeks in the separate STEP UP trial; separate trials do not provide a direct comparison. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary.
Cost and track record differ too: compounded semaglutide renews at $199 every 4 weeks versus $299 for tirzepatide (full terms in the questions below), and semaglutide has the longer post-market record. Which medication fits your health history, goals, and budget is a decision you make with a clinician licensed in California — our full semaglutide vs tirzepatide comparison covers the deeper differences.
Cities served in California
Partner pharmacies ship to every ZIP code in California, including:
- Los Angeles
- San Diego
- San Jose
- San Francisco
- Fresno
- Sacramento
- Long Beach
- Oakland
- Bakersfield
- Anaheim
- Riverside
- Santa Ana
- Irvine
- Chula Vista
- Stockton
- Modesto
California GLP-1 questions
No. California allows a licensed clinician to review your intake by secure message and prescribe without a scheduled video call. They may ask for a video visit only if your history calls for it.
Start the online intake (about 5 minutes). A California-licensed clinician reviews it by secure message, and if a GLP-1 is appropriate, a US-licensed pharmacy ships it to you in 2–3 business days.
Same intake as semaglutide. If appropriate, a California-licensed clinician can prescribe compounded tirzepatide or FDA-approved Zepbound® or Mounjaro®, and explains which fits you.
Yes. A California-licensed clinician can prescribe it for you with a documented clinical reason, and a US-licensed compounding pharmacy prepares it per patient. Brand-name Wegovy® is also available.
Several do. Check that its clinicians are licensed in California, that it uses US-licensed compounding pharmacies, and that it is LegitScript-certified. Pallas serves California.
Medi-Cal dropped weight-loss GLP-1 coverage for adults 21 and older on January 1, 2026; diabetes coverage continues. Compounded GLP-1s are not covered. Pallas is cash-pay, so Medicaid rules do not apply.
One flat cash-pay price, the same in every California ZIP code, no insurance needed. It covers your clinician, check-ins and messaging, and medication ships free once prescribed.
A California-licensed clinician decides after reviewing your intake. GLP-1s are generally considered at a BMI of 30 or more, or 27 or more with a condition like high blood pressure.
Wegovy®, Ozempic®, Zepbound® and Mounjaro® are FDA-approved. Compounded semaglutide and tirzepatide are made per patient by US-licensed pharmacies and are not FDA-approved. Your clinician decides.
Yes. Tell your clinician your current medication, dose and everything else you take during intake. If appropriate, they continue you at a comparable dose. Don't change a prescription on your own.
Mostly stomach-related: nausea, constipation or diarrhea, usually mildest when the dose is raised slowly. They are avoided in pregnancy and with a personal or family history of medullary thyroid cancer or MEN2.
You answer health questions online in about 5 minutes. A California-licensed clinician reviews it by secure message, and if a GLP-1 is appropriate, a licensed pharmacy ships it in 2–3 business days.
Your first order arrives in 2–3 business days, and most patients start low and step up gradually. Your plan renews on a set schedule so refills arrive before you run out; change or cancel anytime in the portal.
Often, yes. Many people take a GLP-1 with metformin, statins or blood pressure medication. List everything you take during intake so your California-licensed clinician can check for interactions.
Most patients start at the lowest weekly dose and step up gradually to limit nausea. Your care team checks in by secure message, and your clinician can adjust your dose before the next shipment.
Yes. California nurse practitioners prescribe under standardized procedures, or independently with AB 890 certification. GLP-1s are not controlled substances, so they can be prescribed by telehealth.
Compounded semaglutide injections are $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. Your clinician, check-ins and messaging are included; shipping is free.
Compounded tirzepatide injections are $179 first month, then $299 every 4 weeks, charged once a clinician prescribes. Cancel anytime. Your clinician, check-ins and messaging are included; shipping is free.
Yes. Wegovy®, Zepbound® and Foundayo™ are FDA-approved for weight management, Ozempic® and Mounjaro® for type 2 diabetes. All are cash-pay: pens from $499 first month, daily pills from $299.
Medi-Cal dropped weight-loss GLP-1 coverage for adults 21 and older on January 1, 2026; diabetes coverage continues. Compounded GLP-1s are not covered. Pallas is cash-pay, so Medicaid rules do not apply.
Two cash-pay paths: stay on Wegovy® or Zepbound® from $499 first month, or a compounded plan from $139 first month if a licensed clinician finds it appropriate. Tell your clinician your current dose.
A decision for you and your clinician. Semaglutide costs less and has the longer track record; tirzepatide acts on two gut-hormone receptors instead of one. The comparison above covers the trials.
Pallas serves all of California with one price for compounded semaglutide: $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. No video visit is required.
Rule changes affecting California
- 2026-07-27 California, South Carolina, and Pennsylvania Medicaid programs eliminated coverage of GLP-1s for weight-loss indications effective January 1, 2026 (Medi-Cal removed Wegovy®, Zepbound®, and Saxenda® for members 21 and older; type 2 diabetes coverage continues in all three, and Medi-Cal keeps narrow exceptions such as Wegovy® for cardiovascular risk reduction). With New Hampshire, logged July 25, all four eliminations reported by KFF are now reflected in the tracker.Medi-Cal Rx provider bulletins (October and December 2025) and KFF Medicaid GLP-1 coverage research; surfaced by our automated source check (PR #45).
From our state-by-state rules tracker. Get an email when a rule changes.
Pallas offers both FDA-approved and compounded medications. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Eligibility and treatment are determined by a US-licensed clinician; results vary. Private pay only (no insurance). Operated by Brentmoor, Inc.